The Spravato Controversy: A Row Over the Drug’s Efficacy Compels...
The UK's drug regulator rejected Janssen's esketamine nasal spray. Why did the US FDA approve it?
Dying to Stay Alive: A Ketamine Disaster
Ketamine treatment, which was being hailed as a ‘miracle cure’, backfired so spectacularly that it very nearly cost me my life.
Lithium, Antidepressants, Esketamine—All No Better Than Placebo?
Peter Simons covers a clinical trial that found lithium ineffective at preventing suicide attempts, an essay by Allen Frances on the overdiagnosis of depression and overprescription of antidepressants, a review of the ineffectiveness and dangers of antidepressants, and an analysis that revealed that esketamine failed five of its six clinical trials.
Psychedelics—The New Psychiatric Craze
Psychedelics have become popular through the potent mixture of financial interests and desperation. Evidence for their beneficial effects is lacking.
MDMA Assisted Psychotherapy and Therapeutic Humility: An Interview with Marcela Ot’alora
Richard Sears interviews Marcella Ot’alora, therapist and principal investigator for MAPS MDMA-assisted psychotherapy.
New Research Questions Safety of Esketamine for Depression
An analysis of FDA adverse event reports related to esketamine shows the potential for negative effects such as suicidal and self-injurious ideation.
John Read – UK Esketamine Approval – Not so Fast
An interview with Professor John Read who joins us to discuss the UK licensing of esketamine nasal spray (Spravato) for so-called ‘Treatment Resistant Depression’. John led a group of 12 academics and professionals who wrote to the UK regulator expressing concerns.
Are Regulatory Bodies Prioritising Drug Company Interests Over Public Safety?
The UK’s Medicines & Healthcare Products Regulatory Agency is refusing to respond to the concerns of psychiatrists, parliamentarians, patients and other experts about the impending licensing of the street drug ketamine as a treatment for depression.
Ketamine for Harmful Drinking: A Look at the Data
New research contends that ketamine can reduce problematic alcohol use but does the data support the claims?
“Flimsy Evidence” for Esketamine as Depression Treatment
A new article documents the “flimsy evidence” behind the recent FDA approval of the party drug esketamine for the treatment of depression.
Ketamine Antidepressant Could Bring Opioid-Like Addiction Risks
From The Independent: "Ketamine-based treatments for severe depression could further fuel the addiction epidemic sweeping the US, researchers have warned, after a new study found the...
Researchers Find Inadequate Reporting of the Dangers of Ketamine Treatment for...
Researchers report that dangerous side effects are not being adequately reported in the trials of ketamine for depression.
The Ketamine Consensus?
From Discover Magazine: A group of psychiatrists from the American Psychiatric Association has recently released A Consensus Statement on the Use of Ketamine in the...
Research Finds Ketamine Does Not Reduce Delirium or Pain After Surgery
Contrary to widely-held belief, a new rigorous trial finds that ketamine is ineffective for delirium and pain associated with surgery, and the drug carries harmful side effects.
The Dangers of Using the Club Drug Ketamine for Depression
From TIME: The club drug ketamine has been found in some small studies to help treat people categorized as having treatment-resistant depression. However, while ketamine has...
New Study Casts Doubt on Efficacy of Ketamine for Depression
A new study, published this month in the Journal of Affective Disorders, investigated the effectiveness of weekly intravenous ketamine injections as a treatment for...
“Warning Over Ketamine Use for Depression”
The Daily Telegraph reports on a warning published in the Medical Journal of Australia that urges doctors not to “jump the gun in prescribing patients the drug ketamine to treat depression.”
Despite “Flurry of Interest,” Ketamine Remains Unproven For Depression
In 2014, then National Institute of Mental Health (NIMH) director, Thomas Insel, speculated that ketamine “might be the most important breakthrough in antidepressant treatment in decades.” A recent review of the research suggests that while ketamine may produce a rapid short-term improvement in depression, the effect is short-lived and the potential for addiction and dependence warrants considerable caution.
“Club Drug Ketamine Gains Traction As A Treatment For Depression”
NPR reports on how ketamine is being used off-label to treat depression.